School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China.
Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Int J Biol Macromol. 2023 May 31;238:124173. doi: 10.1016/j.ijbiomac.2023.124173. Epub 2023 Mar 23.
Aptamers with high affinity and specificity for certain targets have rapidly become a novel class of targeted ligands applicated in drug delivery. Based on the excellent characteristics of aptamers, different aptamer-mediated drug delivery systems have been developed, including aptamer-drug conjugate (ApDC), aptamer-siRNA, and aptamer-functionalized nanoparticle systems for the effective treatment of cancer, which can reduce potential toxicity and improve therapeutic efficacy. In this review, we summarize the recent progress of aptamer-mediated delivery systems in cancer therapy, and discuss the application prospects and existing problems of innovative approaches based on aptamer therapy. Overall, this review aims to better understand the current aptamer-based targeted delivery applications through in-depth analysis to improve efficacy and develop new therapeutic methods which can ultimately improve treatment outcomes for cancer patients.
适体作为一类对特定靶标具有高亲和力和特异性的新型靶向配体,已迅速成为药物递送领域的研究热点。基于适体的优异特性,已开发出多种适体介导的药物递送系统,包括适体-药物偶联物(ApDC)、适体-siRNA 以及适体功能化纳米颗粒系统,用于有效治疗癌症,可以降低潜在毒性并提高治疗效果。本综述总结了适体介导的药物递送系统在癌症治疗中的最新进展,并讨论了基于适体治疗的创新方法的应用前景和存在的问题。总体而言,通过深入分析,本综述旨在更好地了解当前基于适体的靶向递药应用,以提高疗效并开发新的治疗方法,最终改善癌症患者的治疗效果。